AI Article Synopsis
Article Abstract
Immunotherapies based on immune checkpoint blockade have shown remarkable clinical outcomes and durable responses in patients with many tumor types. Nevertheless, these therapies lack efficacy in most cancer patients, even causing severe adverse events in a small subset of patients, such as inflammatory disorders and hyper-progressive disease. To diminish the risk of developing serious toxicities, intratumor delivery of monoclonal antibodies could be a solution. Encouraging results have been shown in both preclinical and clinical studies. Thus, intratumor immunotherapy as a new strategy may retain efficacy while increasing safety. This approach is still an exploratory frontier in cancer research and opens up new possibilities for next-generation personalized medicine. Local intratumor delivery can be achieved through many means, but an attractive approach is the use of gene therapy vectors expressing mAbs inside the tumor mass. Here, we summarize basic, translational, and clinical results of intratumor mAb delivery, together with descriptions of non-viral and viral strategies for mAb delivery in preclinical and clinical development. Currently, this is an expanding research subject that will surely play a key role in the future of oncology.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9917067 | PMC |
| http://dx.doi.org/10.3390/ijms24032676 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Ionic Diode-Based Drug Delivery System.
Adv Mater
December 2024
Department of Material Science and Engineering, Seoul National University, Seoul, 08826, Republic of Korea.
Drug delivery systems hold promise for delivering cytotoxic drugs by controlling the timing and location of the drug release. However, conventional delivery mechanisms often fall short of achieving spatiotemporally controlled yet sustained release, which is crucial for ensuring drug efficacy and minimizing impact on surrounding tissues. Here, an ionic diode-based drug delivery system is reported that is controlled by an electric potential and capable of releasing drugs at scales ranging from nanogram to microgram.
View Article and Find Full Text PDFRevisiting hydrogen peroxide as radiosensitizer for solid tumor cells.
Radiother Oncol
December 2024
Department of Radiotherapy, UZ Brussel, Vrije Universiteit Brussel, 1090 Brussels, Belgium. Electronic address:
Background And Purpose: Tumor hypoxia is the principal cause of clinical radioresistance. Despite its established role as radiosensitizer, hydrogen peroxide (HO) encounters clinical limitations due to stability and toxicity concerns. Recent advancements in drug delivery combine HO with sodium hyaluronate (SH), enabling intratumoral administration of HO.
View Article and Find Full Text PDFEnhancing cancer radiotherapy efficacy using NanOx, a novel oxygenating perfluorocarbon nanoemulsion that reverses tumour hypoxia.
Cancer Lett
December 2024
Trinity St James Cancer Institute, Department of Surgery, Trinity Translational Medicine Institute, Trinity College Dublin.
Radiotherapy is used to treat over 50% of cancer patients. It is often used in combination with surgery, chemotherapy, and immunotherapy, for cancers of the breast, lung, oesophagus, and rectum. Ionising radiation predominantly exerts its anti-cancer effect through both direct DNA damage and indirectly via water radiolysis and the production of reactive oxygen species.
View Article and Find Full Text PDFIntravenous administration of Y-labeled polyoxazoline combined with tumor heating potently inhibits tumor growth in mice.
Int J Pharm
December 2024
Laboratory of Biophysical Chemistry, Kobe Pharmaceutical University, 4-19-1 Motoyamakita-machi, Higashinada-ku, Kobe 658-8558 Japan.
The basic requirements for the development of radiopharmaceuticals for radionuclide therapy of tumors include marked tumor-specific accumulation and long-term intratumoral retention. We have previously reported an indium-111 (In)-labeled thermoresponsive polymer (polyoxazoline (POZ)) that is soluble at body temperature with rapid clearance from normal tissues but self-aggregates in the tumor upon tumor heating treatment. POZ accumulated in the tumor via self-aggregation under hyperthermic conditions and was retained after stopping heat exposure.
View Article and Find Full Text PDFA Near-Infrared-II Fluorescent Nanoprobe Offering Real-Time Tracking of Fenton-Like Reaction for Cancer Chemodynamic Theranostics.
Nano Lett
December 2024
School of Pharmacy, Minhang Hospital, Key Laboratory of Smart Drug Delivery Ministry of Education, State Key Laboratory of Molecular Engineering of Polymers, Fudan University, Shanghai 201203, P.R. China.
Chemodynamic therapy (CDT) utilizing Fenton or Fenton-like reactions to generate cytotoxic hydroxyl radicals by metal ions has become a compelling strategy for cancer treatment. Visualizing intratumoral Fenton or Fenton-like reactions especially at a cellular level in real-time can directly monitor the process of CDT, which is not yet feasible. Here, we present a molecule BADA chelating Cu to form Cu-BADA nanoparticles, exhibiting fluorescence quenching properties through intermolecular electron transfer.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!